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Abstract 
Background  
Cardiovascular diseases represent the greatest burden of global disease. Spending 
on cardiovascular diseases is higher than for other diseases, with the majority being 
spent on drugs. Therefore, these drugs and these diseases are hugely important to 
health systems, society and pharmaceutical companies. The Health Impact Fund 
represents a new mechanism by which pharmaceutical innovators would be rewarded 
on the basis of health impact of their new drugs.  
Objective 
To illustrate the concept of the Health Impact Fund using the example of novel 
anticoagulants for prevention of stroke and thromboembolism in atrial fibrillation.  
Discussion 
By considering existing data and the current situation for novel anticoagulants, we 
suggest that epidemiologic data and modelling techniques can be used to predict 
future trends in disease and the health impact of new drugs.  
Conclusion 
The Health Impact Fund may offer potential benefits to pharmaceutical companies, 
patients and governments and warrants proper investigation. 
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Objective To describe the Health Impact Fund, using the example of novel 
anticoagulants for prevention of stroke and thromboembolism in atrial fibrillation. 
 
Introduction 
Burden of disease due to cardiovascular disease(CVD) is greater than for any other 
disease globally1-3. CVDs are firmly on the global health policy agenda4-6. Spending 
on CVD is greater than for any other disease globally, e.g.hypertension represents 
over 10% of healthcare expenditure globally7,8. Inter-sectoral and inter-disciplinary 
approaches are essential to reduce global CVD4,9.  
 
Most healthcare spending (as in CVD), particularly in low- and middle-income 
countries(LMICs) and particularly out-of-pocket expenditure, is on drugs10-12. Every 
stage of CVD(primary prevention, secondary prevention and acutely) requires drugs. 
Efforts to reduce global healthcare costs must involve drugs used to prevent or treat 
CVD.  
 
Drugs to treat CVD and its risk factors have topped blockbuster charts for over 30 
years, whether anti-clotting drugs(e.g.clopidogrel; Plavix™), statins(e.g.simvastatin, 
Zocor™) or anti-hypertensives(e.g.lisinopril, Carace™)13-14. Some of the largest cases 
of misconduct in trials have occurred in CVDs(e.g.rofecoxib,Vioxx™)15. These drugs 
and diseases are important to health systems, society and pharmaceutical companies 
and improved drug access may produce the greatest gains.  
 
In this review, implications of intellectual property rights on access to medicines and 
innovation are examined. Potential solutions are explored. We will define the Health 
Impact Fund(HIF), a novel proposal to incentivise development and distribution of 
drugs depending on global health impact. The potential role of the HIF will be 
considered with respect to novel anticoagulants(NOACs) for stroke prevention in atrial 
fibrillation(AF). 
 
Intellectual property rights 
Until 1994, intellectual property rights were enforced strictly in wealthy countries, 
whereas LMICs had much weaker patent laws, if any. . Since 1994, LMICs agreed to 
institute TRIPS(Trade-Related Aspects of Intellectual Property Rights)-compliant 
systems16. TRIPS became more constraining as increased numbers of countries 
implement patent exclusivity, shaping all intellectual property rights, including drugs. 
Although TRIPS implementation and affordability are not the only factors contributing 
to access, TRIPS has probably widened global health inequalities17-19(figure 1). 
 
New technologies, including drugs, have been “produced by companies from high-
income countries for high-income markets” 20,21. The industries and the incentives are 
not aligned with access, which acts as both determinant and consequence of 
inequalities in health, income and development17,19. Access to drugs is one of global 
health’s greatest challenges. Even for cheap, generic drugs with proven efficacy, rates 
of use and access are suboptimal.  A recent study of global secondary CVD prevention 
showed that few individuals took antiplatelet drugs(25·3%), beta-blockers(17·4%), 
angiotensin converting enzyme-inhibitors(ACEIs), ARBs(angiotensin 2-receptor 
blockers)(19·5%), or statins(14·6%)22. These data suggest that health system 
improvements are needed to affect drug access. New CVD drugs may not have a 
major effect when established drugs are so under-used. However, in certain instances, 
new drugs have transformed disease management(e.g. statins in CVD prevention or 
ACEIs for hypertension). Intellectual property rights can directly influence 
affordability,sustainability and rational selection by practitioners by highlighting new 
drugs with greatest health impact. Indirectly,pharmaceutical companies may be 
incentivised to improve infrastructure and proper use by health professionals and 
individuals(figure 1).Therefore, intellectual property rights and new drugs may have 
wide implications on global health impact. 
   
Ethical and human rights arguments have been used for access to healthcare4,23,24, 
which should guide governments and industries to produce accessible medicines. 
However, access is not simply based on cost and affordability. If other factors are 
neglected, benefits of available drugs will not be realised. Even if appropriate, 
essential medications are available, their correct use is not guaranteed17,19. 
Governments, pharmaceutical companies, society and individuals all have a role to 
play. However, responsibility for providing access to drugs is in the hands of the 
stakeholders with greatest capability, namely pharmaceutical companies and 
governments19. Cost of drugs represents a unique opportunity to change the current 
paradigm(figure 1).     
  
Current solutions 
Where cost of medications restricts their provision, several potential solutions have 
been utilised. First, generic drugs are cheaper than branded versions. Indian 
companies supply low-cost generics(including CVD drugs), domestically, to other 
LMICs and increasingly to wealthier countries as well. If generics are used to substitute 
branded drugs, especially in CVD, economic and public health benefits are likely25. 
Until 2005, India could avoid introducing product patents, although process patents 
were already available prior to TRIPS26,27. However, a recent analysis of new patents 
filed in India since 2005 suggests no relationship with disease burden or public health 
priorities28.  
 
Second, charitable donations from wealthy countries and pharmaceutical companies 
are possible. . Since treatments for CVD) are often long-term, if not lifelong, a more 
sustainable supply is needed. 
 
Proponents of TRIPS state that it contains provisions which allow prioritisation of 
public health needs. Parallel imports are imports of a patented or trademarked product 
from a country where it is already marketed29. Compulsory licensing is when a 
government allows someone else to produce the patented product or process without 
the consent of the patent owner30. However, LMICs have not adequately used existing 
provisions with public health consequences31. In summary, CVD drugs are neither 
available nor affordable in many countries, particularly in the public sector32.  
 
The Health Impact Fund 
There are no incentives for pharmaceutical companies to develop, market or deliver 
drugs which will have maximal impact on global health. Such mechanisms would make 
greatest difference in CVDs, which represent largest disease burden, highest drug 
spending and greatest number of new drugs in recent years.  
 
The Health Impact Fund (HIF) would reward pharmaceutical companies in proportion 
to global health impact of their innovation17. As a global agency underwritten by 
governments, it would offer pharmaceutical companies the option to register new 
products. Registration would entitle innovators to receive, for a defined period(e.g.10 
years), a share of fixed renumeration from a reward pool. The fund would disburse at 
least US$6 billion annually, paying each registrant a share corresponding to 
contribution to global health impact of all registered drugs, as estimated with a global 
health impact assessment exercise(web appendix 1). In return, the registrant would 
sell the medicine wherever needed at no more than the lowest feasible cost of 
production and distribution. After the reward period, free licences would enable generic 
manufacture and sales17.  
 
The HIF has gained momentum33,34, but the next challenges are finding PCs willing to 
license their novel products and credible methodology for health impact assessment 
to test the HIF.  
 
New drugs and new trials 
Atrial fibrillation (AF) is the commonest arrhythmia and is a major cause of stroke and 
thromboembolism35. NOACs are an alternative to warfarin, the mainstay of 
anticoagulation for over 50 years 36-37. In the last 3 years, following successful phase 
3 clinical trials, three agents(dabigatran, apixaban and rivaroxaban) have been 
incorporated into guidelines worldwide and more NOACs are in the pipeline38-40. As 
with statins, ACEIs, ARBs and other CVD drug classes, “me-too” agents are 
anticipated and trials are already underway41-44. “Me-too" drugs are expensive and do 
not serve society well41-43. The HIF may combine profits with patient benefit in a 
mutually beneficial manner.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
Imagine that the pharmaceutical companiesproducing NOACs registered with the HIF. 
Based on trials or predicted trial outcomes (for edoxaban44), the reward for each 
NOAC would be estimated. Most NOACs have been subject to trials in deep-vein 
thrombosis(DVT) prior to trials in AF. Potential impact of NOACs could be estimated 
based on DVT trials if AF trials were not yet completed. 
 
Subgroup analyses are often reported in trials to quantify drug effects in different 
subpopulations. Ideally, subgroups should be defined before trial initiation, but post-
hoc analyses are often reported. Although post-hoc analyses have possible biases 
and limitations, they may be useful for modelling. Possible subgroups for NOACs 
include age, renal function or other cardiovascular risk factors38-40, 45-46.  
 
NOACs, like warfarin, and all drugs, have risks(excess bleeding) as well as benefits 
(prevention of stroke/thromboembolism). Trial data may be used to estimate risks as 
well as benefits, and to compare different agents. Health impact assessment will aim 
to model incremental benefit of new drugs versus current “gold-standard” therapy or 
other new drugs. For anticoagulants, “net clinical benefit” balances risk of bleeding 
versus benefit of stroke prevention47 and and has been used to compare NOACs and 
warfarin48-49. Similar concepts could be used for health impact assessment of other 
new drugs.   
 
Identifying datasets 
National and local datasets offer invaluable resources from which the target population 
can be modelled, e.g. the UK’s Clinical Practice Research Datalink50 and the Danish 
national healthcare database48. Regional variations occur in distribution of risk factors 
and disease51. The more accurately these variations can be incorporated into models, 
the better the estimation of drug effects. The Global Burden of Disease(GBD) Study 
has revolutionised knowledge of prevalence, time trends and predictions for disease 
and risk factors52,53. GBD data could be used to model patient populations and drug 
effects at country level. However, there is variation in missing data and methodologies 
of data collection across countries; e.g.there is incomplete death registration in many 
LMICs; with some having no death registration data at all54-55.  
 
Registries can be local, regional, national or multi-national56. AF registries have 
highlighted risk associations57 and have been used to model effects of population-wide 
implementation of NOACs58 and differences between “real-world” and “clinical trial” 
effects59. Global registries can be powerful in learning about current risk factor and 
disease trends, and clinical practice60-61. However, registries also have limitations, 
including variable data selection and data quality due to varying methodologies62.  
 
Tools are increasingly used to predict risk of disease outcomes in different 
populations. In AF, several risk prediction tools for stroke/thromboembolism and 
bleeding are validated, widely used 63-66, and have been used to define subgroups 
within studies49. In individuals, these tools allow trial results to be personalised; 
e.g.stroke/thromboembolism risk associated with each level of CHA2DS2-VASc score 
has been investigated in multiple studies. If the CHA2DS2-VASc distribution can be 
estimated in a population, the drug effects at each level of CHA2DS2-VASc may be 
modelled, for the health impact assessment.   
 
Optimal data sources will be identified for a particular context(preferably at multiple 
levels,i.e. local, regional, national)67. Growing transparency and public availability of 
data from trials will benefit the HIF68-69.  
 
Modelling 
Analyses of population impact, potential cost and comparative analysis of NOACs 
would be required . The population attributable risk is the proportion of a given disease 
which can be attributed to a specific risk factor(e.g. AF), whether clinical70 or 
subclinical71and may be useful for estimating burden of AF and stroke/ 
thromboembolism. The “potentially modifiable burden” of disease (e.g. stroke) may be 
useful in describing potential benefits of drugs72. 
 
The IMPACT model shows how evidence can inform public health policy73,74. The 
“policy effectiveness-feasibility loop” involves:(a)epidemiological modelling; 
(b)situation analysis; and (c)option appraisal74. The first stage can be adapted to 
include modelling of effects of new drugs so that this same framework can be applied 
to health impact assessment. The IMPACT model has been used to estimate 
proportion of change in rates of disease which can be attributed to changes in a 
particular risk factor75-76.  The IMPACT model has largely been restricted to CHD, but 
could be used in other diseases.  
 
Projections of AF burden and representativeness of trial populations for NOACs have 
been studied50,76. Trial data can be used to model different levels of prescription, 
adherence, cost and other environmental factors. Cost-effectiveness analyses are 
another data source,77,78 .subject to quality of cost and efficacy data. Incremental cost-
effectiveness data are of greatest relevance and value to the HIF but often ignored in 
favour of “cost-effectiveness thresholds”79-80. As with all modelling, limitations and 
ranges of data must be acknowledged transparently.Different scenarios may be 
constructed within models to simulate impact of several competing drugs, e.g.(a) 
competing drugs have sustained and equal sales;(b)one of the drugs overtakes its 
competitors; (c) none of the drugs are taken up to an appreciable extent. Several 
factors such as adherence, side effects of new drugs, indications included in the drug 
license and ongoing data collection will be considered as the optimal method of health 
impact assessment is finalised. “Scenario planning” begins by identifying focal issues 
or decisions(e.g.effect of introduction of a NOAC on use of warfarin, use of NOACs, 
access to drugs and rates of stroke/thromboembolism) and predicts future 
environment81-84. Four factors shape future scenarios83:  
 
1. Social  
Social factors, include: increasing burden of  AF and stroke due to ageing populations 
and demographic transition, values systems(e.g.more demand for equity and 
corporate social responsibility), lifestyle(e.g.adherence), demand(increasing demand 
for NOACs from providers and patients), and political energy (to enforce uptake of new 
drugs). 
 
2. Economic  
Macroeconomic (e.g. “How will international trade flow and exchange rates affect the 
price of drugs?”; “How will global pharmaceutical companies respond to 
pharmaceutical companies from LMICs?”) and microeconomic factors(e.g.“How much 
appetite is there in the system for increased spending on new drugs?”; What financial 
protections protect patients from catastrophic out-of-pocket expenditures on drugs?; 
“How might the structure of pharmaceutical companies change?”; “How much 
partnership will exist between different producers of NOACs?”) influence uptake and 
effect of new drugs. 
3. Political  
Local(e.g.interpretation of practice guidelines and evidence), regional(e.g.competition 
between practice in other centres; competition between existing anticoagulation 
services and new infrastructure for NOACs), national(e.g.implementation of NICE 
guidelines) and international(e.g.implementation of TRIPS) environments can affect 
uptake and effectiveness of new drugs. Across all spheres, level of funding within the 
health sector and for drugs specifically must be considered85,86. 
   
4. Technological  
Direct evidence for effectiveness obviously influences how new drugs are incorporated 
into clinical practice and health systems. Evidence can change over time, relating to 
“real-world” effects, side-effects and new clinical indications: e.g.NOACs have proven 
effectiveness in treatment of DVT87. Indirect evidence includes data regarding other 
competing drugs, new and old. As “me-too” NOACs emerge, their effectiveness and 
cost-effectiveness may affect and limit uptake and impact of first-generation NOACs. 
Web appendix 2 highlights an example of scenario modelling. 
 
Reward mechanism 
Health impact assessment should be based on as much high-quality evidence as 
possible and available. Although models have imperfections and assumptions, any 
measure of population-based impact will improve on the current paradigm. At present, 
pharmaceutical company marketing strategies focus on trial data. Health impact 
assessment requires a longer-term view from both pharmaceutical companies and 
policymakers. It would be expensive, given the need to assess multiple medicines 
globally. However, there would also be economies of scale from assessing many 
medicines at the same time, and efficiencies from assessing the same medicine year 
after year. 
 
In consultation with stakeholders(including pharmaceutical companies), a reward for 
a specific health impact threshold will be agreed. If this target is met, then 
pharmaceutical companies will receive this agreed reward. Health impact assessment 
by independent assessors would occur annually to estimate actual impact of new 
drugs and to determine rewards due to pharmaceutical companies. The HIF rewards 
any company that produces an effective new drug in proportion to how well the drug 
works, provided that the innovator agrees to sell it at cost price. After the 10-year 
reward period, the company would also offer free licences to enable generic 
manufacture and sales. Pharmaceutical companies may be rewarded based on early 
results and longer-term results may later emerge, showing less benefit or potentially 
harms associated with the drug. The HIF reward allocated to a drug will be evaluated 
annually on available evidence and can be changed. Therefore, if a drug actually 
causes harm, it will not be rewarded. A PC will only receive full reward if the agreed 
target of impact is met. A consequence of using life-years or disability- or quality-
adjusted life years as the primary health impact assessment modelling outcome may 
be that highly effective treatments for rare diseases occurring early in life will have a 
health impact reward similar to a moderately effective treatment for a common disease 
occurring in adulthood. 
 
Box 1 summarises potential benefits of the HIF for pharmaceutical companies, 
patients and governments. 
 
Conclusions 
The current intellectual property rights regime and the way in which novel drugs are 
evaluated after proof-of-efficacy in trials are inadequate. The HIF offers an alternative 
mechanism by which pharmaceutical companies could be rewarded based on global 
health impact of their novel drugs. Using the example of NOACs for stroke prevention 
in AF, feasible methods of health impact assessment have been suggested. The same 
principles apply to other current examples, including antiplatelet agents post-
STEMI89,90. Trials, registries and other datasets offer potential for modelling future 
trends in disease burden as well as impact of novel drugs. 
 
Judicious use of available data and scenario modelling represent a significant 
improvement compared with the status quo where rewards have no association with 
“real-world” impact of drugs. Feasibility of prospective health impact assessment of 
novel drugs must now be properly tested using different drugs in different disease 
areas, in order to take forward the concept of the HIF. There is a growing movement 
to increase the transparency of pharmaceutical companies and to improve access to 
their drugs91.The HIF may be the most sustainable and feasible solution. 
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